Apogee Therapeutics Logo
US03770N1019
APGE

Apogee Therapeutics

Previsión

El precio objetivo medio de los analistas es de 118,39 € (+1,54 %). La mediana es de 123,03 € (+5,52 %).

Comprar
  2
Mantener
  12
Vender
  0

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • Apogee Therapeutics reaches record high at $134.89

    Apogee Therapeutics' stock reached a record high of $134.89, representing a year-to-date gain of 256.92%. InvestingPro notes the stock may appear overvalued at this level and that its fair-value estimate is substantially lower. Apogee has more cash than debt but was unprofitable over the past twelve months. Shareholders approved AbbVie's acquisition, which values the company at $10.9 billion ($135.11 per share) and prompted analyst downgrades and adjusted price targets. » Más en de.investing.com


  • Apogee Therapeutics reaches record high at $134.47 ahead of takeover by AbbVie

    Apogee Therapeutics shares rose to an all-time high of $134.47 and show a year-to-date return of around 270% with a market capitalization of $10.08 billion. AbbVie announced an acquisition agreement at $135.11 per share, valuing Apogee at about $10.9 billion, while InvestingPro and RSI indicators point to overvaluation and overbought conditions. After the announcement, Mizuho and UBS downgraded the stock from buy to neutral, while RBC raised its price target to $97; Apogee also closed R&D agreements with Paragon Therapeutics and appointed new directors. » Más en de.investing.com


  • Apogee Therapeutics sold by Baron Capital after AbbVie agrees $135.11-per-share buyout

    Baron Health Care Fund sold its position in Apogee Therapeutics following AbbVie's announced acquisition of Apogee for $135.11 per share, a 49.5% premium to the prior close. The fund cited Apogee as a key contributor to its biotechnology stock selection during Q2 and reported overall quarterly gains. Apogee shares have risen sharply over the past year and the deal values the company at roughly $10.11 billion. » Más en finance.yahoo.com


  • Apogee Therapeutics reaches record high of $134.34

    Shares of Apogee Therapeutics rose to an all-time high of $134.34, about 243% above last year; market capitalization is roughly $10.05 billion. AbbVie announced a takeover agreement at $135.11 per share, valuing the company at about $10.9 billion, after which analysts at Mizuho and UBS downgraded the stock to "Neutral" and cited price targets around $135. Additional developments: a partnership with Paragon Therapeutics to develop an IL-31R antibody, an RBC price target of $97, and the move of zumilokibart into phase III trials. » Más en de.investing.com


  • Apogee Therapeutics reaches record high of $133.88 after takeover agreement with AbbVie

    Apogee Therapeutics' stock rose to a record high of $133.88, bringing market capitalization to about $10.02 billion. InvestingPro rates the stock as overvalued versus its fair value and notes an overbought RSI, despite strong performance (+250% over the past year). AbbVie announced a definitive takeover agreement at $135.11 per share (around $10.9 billion), after which several analysts downgraded their ratings to neutral and set price targets near $135. Additionally, Apogee announced collaboration agreements with Paragon Therapeutics to develop antibodies against the interleukin-31 receptor, and confirmed board elections and approved shareholder proposals. » Más en de.investing.com

Datos financieros

En el último trimestre, Apogee Therapeutics tuvo unos ingresos de 0 € y un beneficio neto de -75,23 M €

(EUR) junio de 2026
YoY
Ingresos 0 -
Beneficio bruto 0 -
Beneficio neto -75,23 M 34,15 %
EBITDA -73,42 M 31,86 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
7656,71 M €
Número de acciones
62,2 M
Máximo/mínimo de 52 semanas
123,11 € - 32,25 €
Dividendos No
Beta
0,34
Ratio P/E
-31,12
Ratio PEG
6,57
Ratio P/B
8,53
Ratio P/S
0,00

Perfil de la empresa

Apogee Therapeutics, Inc., a través de su filial, opera como una compañía de biotecnología que desarrolla biológicos para el tratamiento de la dermatitis atópica (AD), la enfermedad pulmonar obstructiva crónica (EPOC, COPD) y otras indicaciones relacionadas con la inflamación y la inmunología. La compañía desarrolla principalmente APG777, un anticuerpo monoclonal (mAb) de semivida extendida de administración subcutánea (SQ) para la AD; y APG808, un mAb de semivida extendida SQ para la EPOC. Sus programas en etapas más tempranas incluyen APG990, un mAb de semivida extendida SQ para el tratamiento de la AD; y APG222, anticuerpos de semivida extendida SQ para la AD. La compañía fue fundada en 2022 y tiene su sede en Waltham, Massachusetts.

Nombre
Apogee Therapeutics
CEO
Michael Thomas Henderson
Sede Waltham, ma
Estados Unidos
Sitio web
Industria
Productos alimenticios
Salida a bolsa
14/07/2023
Empleados 261

Símbolos bursátiles

Bolsa Símbolo
NASDAQ
APGE
🍪

Parqet  usa cookies. Más información